SES Selects Arianespace to Launch EAGLE-1 Satellite for Europe’s Quantum Cryptography
The EAGLE-1 satellite, which will support the end-to-end secure Quantum Key Distribution (QKD) system for Europe, will be launched for SES by Arianespace on a Vega C rocket from French Guiana as early as Q4 2024. The satellite will be placed into Low Earth Orbit (LEO). The EAGLE-1 project comprising satellite and ground infrastructure, is developed by SES and its consortium of 20 European partners, with the European Space Agency (ESA) and the European Commission support.
Under the recently-signed agreement with ESA, SES and its partners will design, develop, launch and operate a satellite-based end-to-end QKD system for the purpose of testing and validating space-based secure transmission of cryptographic keys. The first European sovereign space-based QKD system will include the dedicated low earth orbit (LEO) EAGLE-1 satellite and state-of-the-art QKD operations centre in Luxembourg. In the scope of EuroQCI, the EAGLE-1 satellite will enable early access, validation, and integration of space-based QKD for EU Member States.
“Building the EAGLE-1 end-to-end system for secure data transmission and validating the long-distance Quantum Key Distribution technology is an innovative project that will benefit the EU Member States,” said Ruy Pinto, Chief Technology Officer at SES. “We have been working with Arianespace for decades to deliver our satellites into space and are delighted for them to be onboard to launch the EAGLE-1 satellite into orbit.”
“We are delighted and honored by this renewed mark of confidence from the leading global content connectivity service provider SES,” noted Marino Fragnito, Director of Arianespace’s Vega business unit. “Over the last 38 years, Arianespace has carried out 42 launches for its longstanding partner, and Vega C will now continue this successful track record. It is a great honor for us to support our customer’s ambitions and to be part of this mission that aims at implementing Europe’s satellite-enabled cybersecurity technology.”
Following the launch, the EAGLE-1 satellite will complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions, as well as critical business sectors, early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
The EAGLE-1 project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Vega C, the new European light launcher successfully passed its inaugural flight on July 13 and now enters its operational phase under the responsibility of Arianespace. With this contract, Vega C backlog includes over 40 satellites contracts.
Vega C development program has been managed by ESA with 12 Member States of the Agency. Avio Spa (Colleferro, Italy) is the industrial prime of the Vega launch system. Vega C has been upgraded with more powerful first and second stage Solid Rocket Motors and with a larger fairing, which significantly increases payload mass and double allowable volume as compared to Vega. The launcher also better meets the specific needs of small spacecrafts, thanks to its improved SSMS dispenser and to its AVUM+ that allows seven re-ignitions instead of five. Vega C can thus deliver to three different separation orbits for its multiple payloads within the same mission, instead of the two previously possible with Vega.
For more information, visit the EAGLE-1 Newsroom
Follow SES on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Follow Arianespace on:
Twitter | YouTube | LinkedIn | Instagram
About ESA
The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int
The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About Arianespace
Arianespace uses Space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited over 1,100 satellites since 1980. Arianespace is responsible for operating the new-generation Ariane 6 and Vega C launchers, developed by ESA, with respectively ArianeGroup and Avio as industrial primes. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 15 other shareholders from the Ariane and Vega European launcher industry, and ESA and Cnes as censors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006349/en/
Contact information
For further information:
Suzanne Ong
External Communications, SES
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom